Randomized controlled trial to evaluate the prediction of the effectiveness for HLA-oriented therapy in gastric and colorectal cancer.

Randomized controlled trial to evaluate the prediction of the effectiveness for HLA-oriented therapy in gastric and colorectal cancer. - Randomized controlled trial to evaluate the prediction of the effectiveness for HLA-oriented therapy (JCTB trial).

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037475

Enrollment

600

Registered

2019-07-29

Start date

1990-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer Colorectal cancer

Interventions

HLA B40(+) HLA B51(+) PSK(-) PSK(+): PSK was administered orally from 14 days after gastrectomy at a dose of 3.0g/day and at least at a dose of over 270g. Per os fluoropyrimidine prodru (5-FU 150

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Primary T2-T4 gastric and colorectal cancer patients who gave informed consent. MMC injection and the selection of F drugs was depended on an attending doctor.

Exclusion criteria

Exclusion criteria: 1. Double cancer. 2. Prior cytotoxic or radiation therapy. 3. Abnormal bone marrow, hepatic and renal function 4. Severe cardiac, hepatic and lung failure, and an attending doctor was considered unsuitable.

Design outcomes

Primary

Measure	Time frame
Five year overall survival after gastrectomy	—

Countries

Japan

Contacts

Public ContactKyoji Ogoshi

Tokai University Department of Surgery

ogoshi@is.icc.u-tokai.ac.jp0463-96-6163

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026